Advertisement

Topics

Sensipar® (cinacalcet HCl) Company Profile

19:16 EST 23rd November 2017 | BioPortfolio

Sensipar® (cinacalcet HCl) is an innovative, first-in-class, oral therapy indicated to treat hyperparathyroidism (excessive levels of parathyroid hormone) caused by chronic kidney disease; it is approved for use in patients who are receiving dialysis. It is also indicated to treat elevated calcium levels in patients with malignant tumors of the parathyroid gland.


News Articles [10 Associated News Articles listed on BioPortfolio]

Sensipar API Insights, 2017 [Report Updated: 10072017] Prices from USD $500

DelveInsight's, Sensipar API Insights, 2017 report provides product and API manufacturers details across the globe along with the location. The report gives the clear idea on the country wise DMF fil...

Sensipar Drug Insights, 2017 [Report Updated: 10072017] Prices from USD $1000

DelveInsight's pharmaceuticals report, Sensipar Drug Insights, 2017 highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report ...

Global and Chinese Cinacalcet HCL Industry, 2017 Market Research Report [Report Updated: 21062017] Prices from USD $3000

The 'Global and Chinese Cinacalcet HCL Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Cinacalcet HCL industry with a focus on the Chi...

Human medicines European public assessment report (EPAR): Mimpara, cinacalcet, Revision: 18, Authorised

European Commission (EC) Approves Expanded Use Of Mimpara (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis

  Life Sciences Jobs   ...

Amgen Release: European Commission (EC) Approves Expanded Use Of Mimpara (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis

  Life Sciences Jobs   ...

European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of ...

"Secondary HPT is a serious and complex condition, and there are currently limited treatment options available for pediatric patients living with this disease," said Sean Read more...

Pediatric Exclusivity and the Regulatory Authority of the FDA

This Viewpoint uses the legal dispute between Amgen and the US Food and Drug Administration (FDA) regarding the FDA’s denial of market exclusivity for cinacalcet to discuss the FDA policy granting 6...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Sensipar [State of Florida DOH Central Pharmacy]

Sensipar (cinacalcet) Tablets

Sensipar [Amgen, Inc]

These highlights do not include all the information needed to use Sensipar safely and effectively. See full prescribing information for Sensipar. Sensipar (cinacalcet) TabletsInitial U.S. Approval: 20...

PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

Intraoperative and postoperative hyperkalaemia after total parathyroidectomy following exposure to cinacalcet in sixteen patients for renal hyperparathyroidism.

Our clinical observation suggested that patients with prior treatment with cinacalcet and undergoing parathyroidectomy for renal hyperparathyroidism had greater acute hyperkalaemia in the intraoperati...

Cinacalcet in peritoneal dialysis patients: one-center experience.

Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet. Most studies were done only in hemodialysis patients, with few data from peritoneal dial...

Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review.

Patients with end-stage renal disease (ESRD) have a decreased quality of life (QoL), which is attributable in part to ESRD-related hyperparathyroidism (HPT). Both cinacalcet and parathyroidectomy (PTx...

Improved regeneration and de novo bone formation in a diabetic zebrafish model treated with Paricalcitol and Cinacalcet.

Bone changes related to diabetes have been well stablished, but few strategies have been developed to prevent this growing health problem. In our work we propose to investigate the effects of calcitri...

Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism.

Clinical Trials [30 Associated Clinical Trials listed on BioPortfolio]

E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events

The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with...

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are s...

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

The purpose of this study is to evaluate the effects of cinacalcet on bone function and bone cells in patients with kidney disease who are receiving dialysis.

Evaluation of a Cincalcet Suppression Test

The aim of the study is to compare the results of a parathyroid hormone (PTH)suppression test using a single oral tablet of cinacalcet in two groups of subjects: 1- a group of healthy adul...

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2. To explore the impact o...

Companies [3 Associated Companies listed on BioPortfolio]

Sensipar® (cinacalcet HCl)

Sensipar® (cinacalcet HCl) is an innovative, first-in-class, oral therapy indicated to treat hyperparathyroidism (excessive levels of parathyroid hormone) caused by chronic kidney disease; it is appr...

NPS Pharmaceuticals

NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervo...

Sensipar

Nil

More Information about "Sensipar® (cinacalcet HCl)" on BioPortfolio

We have published hundreds of Sensipar® (cinacalcet HCl) news stories on BioPortfolio along with dozens of Sensipar® (cinacalcet HCl) Clinical Trials and PubMed Articles about Sensipar® (cinacalcet HCl) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sensipar® (cinacalcet HCl) Companies in our database. You can also find out about relevant Sensipar® (cinacalcet HCl) Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Dialysis
In medicine, dialysis is a process for removing waste and excess water from the blood, and is primarily used to provide an artificial replacement for lost kidney function in people with renal failure. Dialysis may be used for those with an acute disturba...


Corporate Database Quicklinks



Searches Linking to this Company Record